NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Telomere Therapeutics

Telomere Therapeutics

Private
BarcelonaHealthcare & Life Scienceshttps://telomere-tx.com/

Last Round

Accelerator

Dec 13, 2023

Total Funding Raised

$2.32M

Company Overview

Telomere Therapeutics is a gene therapy company developing disease modifying treatments for unmet medical needs, pioneering the repair of telomeres to treat organ fibrosis and other telomere-dysfunction syndromes.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

gene therapytelomere repairAAV gene therapyidiopathic pulmonary fibrosisIPFlongevity biotechtelomere dysfunctionTERT gene therapyregenerative medicineadeno-associated virusAAVanti-aging therapyfibrotic diseasescellular agingpreclinical biotechtelomerase reverse transcriptase

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Telomere Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Telomere Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Telomere Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorDec 13, 2023
GrantJan 1, 2022
SeedMay 25, 2021

Key People

Founding team and executive leadership

Michael Tadros

CEO

Executive Team

Telomere Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 1, 2025

    Monthly visitors increased 22,253% MoM, from 17 to 3.8K.

  • Oct 30, 2024

    Monthly visitors grew 529% MoM, from 286 to 1.8K.

Telomere Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Telomere Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Telomere Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBarcelona
Employee Range5
Year Founded2020
Last FundingDec 13, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.